The data suggest that antibodies to human papillomavirus type 16 — a leading cause of throat cancer — can be detected decades before a patient's clinical diagnosis.
A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.
The firm said that the new instrument, which prepares slides for cytology and aliquot samples for molecular testing, offers workflow benefits to clinical labs.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
